Estrous Cycle Modulates Ovarian Carcinoma Growth
Open Access
- 30 April 2009
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 15 (9) , 2971-2978
Abstract
Purpose: The effects of reproductive hormones on ovarian cancer growth are not well understood. Here, we examined the effects of estrous cycle variation and specific reproductive hormones on ovarian cancer growth. Experimental Design: We investigated the role of reproductive hormones in ovarian cancer growth using both in vivo and in vitro models of tumor growth. Results:In vivo experiments using the HeyA8 and SKOV3ip1 ovarian cancer models showed that tumor cell inoculation during proestrus significantly increased tumor burden (251-273%) compared with injection during the estrus phase. Treatment of ovariectomized mice with 17β-estradiol resulted in a 404% to 483% increase in tumor growth compared with controls. Progestins had no significant effect, but did block estrogen-stimulated tumor growth. Tumors collected from mice sacrificed during proestrus showed increased levels of vascular endothelial growth factor (VEGF) and microvessel density compared with mice injected during estrus. HeyA8, SKOV3ip1, and mouse endothelial (MOEC) cells expressed estrogen receptor α and β and progesterone receptor at the protein and mRNA levels, whereas 2774 ovarian cancer cells were estrogen receptor–negative. In vitro assays showed that 17β-estradiol significantly increased ovarian cancer cell adhesion to collagen in estrogen receptor–positive, but not in estrogen receptor–negative cells. Additionally, 17β-estradiol increased the migratory potential of MOEC cells, which was abrogated by the mitogen-activated protein kinase (MAPK) inhibitor, PD 09859. Treatment with 17β-estradiol activated MAPK in MOEC cells, but not in HeyA8 or SKOV3ip1 cells. Conclusion: Our data suggest that estrogen may promote in vivo ovarian cancer growth, both directly and indirectly, by making the tumor microenvironment more conducive for cancer growth.Keywords
This publication has 66 references indexed in Scilit:
- Functional significance of VEGFR‐2 on ovarian cancer cellsInternational Journal of Cancer, 2008
- Non-genomic effects of 17β-estradiol in activation of the ERK1/ERK2 pathway induces cell proliferation through upregulation of cyclin D1 expression in bovine artery endothelial cellsGynecological Endocrinology, 2007
- Endocrine signaling in ovarian surface epithelium and cancerHuman Reproduction Update, 2006
- Estradiol increases VEGF in human breast studied by whole-tissue cultureCell and tissue research, 2006
- Effects of oestradiol and tamoxifen on VEGF, soluble VEGFR-1, and VEGFR-2 in breast cancer and endothelial cellsBritish Journal of Cancer, 2005
- Sex cycle modulates cancer growthBreast Cancer Research and Treatment, 2005
- Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and AngiogenesisJournal of Clinical Oncology, 2005
- Hemostatic effects of high-dose megestrol acetate therapy in patients with advanced gynecological cancerGynecological Endocrinology, 2001
- Biological effects of progestins in breast cancerGynecological Endocrinology, 1999
- Biological effects of progestins in breast cancerGynecological Endocrinology, 1999